Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.

Malignancies represent a major cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected patients. The introduction of combined antiretroviral therapy has modified the spectrum of malignancies in HIV infection with a decreased incidence of acquired immunodeficiency syndrome (AIDS) malignancies such as Kaposi's sarcoma and non-Hodgkin's lymphoma due to partial immune recovery and an increase in non-AIDS-defining malignancies due to prolonged survival. Management of HIV-infected patients with cancer requires a multidisciplinary approach, involving both oncologists and HIV physicians to optimally manage both diseases and drug interactions between anticancer and anti-HIV drugs. The French CANCERVIH group presents here a review and an experience of managing non-AIDS malignancies in HIV-infected individuals.

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  S. Eymard-Duvernay,et al.  Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers , 2016, AIDS.

[3]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[4]  M. Rudek,et al.  Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib , 2015, Cancer Chemotherapy and Pharmacology.

[5]  D. Costagliola,et al.  High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[7]  D. Rothenbacher,et al.  Optimal management of cervical cancer in HIV-positive patients: a systematic review , 2015, Cancer medicine.

[8]  E. Engels,et al.  Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Costagliola,et al.  Trends in survival after cancer diagnosis among HIV‐infected individuals between 1992 and 2009. Results from the FHDH‐ANRS CO4 cohort , 2015, International journal of cancer.

[10]  M. Meyerson,et al.  The tumor virus landscape of AIDS-related lymphomas. , 2015, Blood.

[11]  R. Little,et al.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. , 2015, Blood.

[12]  J. Vose,et al.  Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study , 2015, Cancer.

[13]  A. García-Carrancá,et al.  Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men , 2014, BMC Infectious Diseases.

[14]  A. Antinori,et al.  Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial , 2014, The Lancet.

[15]  X. Duval,et al.  [Anal cancer in HIV patients]. , 2014, Bulletin du cancer.

[16]  David W. Haas,et al.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. , 2014, Annals of internal medicine.

[17]  M. Hleyhel.  Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort , 2014, AIDS.

[18]  F. Lert,et al.  Tobacco Smoking in HIV-Infected versus General Population in France: Heterogeneity across the Various Groups of People Living with HIV , 2014, PloS one.

[19]  G. Copeland,et al.  Cancer treatment disparities in HIV-infected individuals in the United States. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P Baas,et al.  2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Torres,et al.  Management of HIV infection in patients with cancer receiving chemotherapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.

[23]  D. Samuel,et al.  Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies? , 2014, AIDS.

[24]  S. Bojesen,et al.  Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV , 2014, AIDS.

[25]  Richard D Moore,et al.  Prospective CT Screening for Lung Cancer in a High-Risk Population: HIV-Positive Smokers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  K. Arheart,et al.  Tobacco Smoking Increases Immune Activation and Impairs T-Cell Function in HIV Infected Patients on Antiretrovirals: A Cross-Sectional Pilot Study , 2014, PloS one.

[27]  P. Morlat,et al.  Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000 , 2014, AIDS.

[28]  R. Sullivan,et al.  A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus‐positive patients with cancer: AIDS Malignancy Consortium trial AMC 061 , 2014, Cancer.

[29]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[30]  I. Melero,et al.  Orchestrating immune check-point blockade for cancer immunotherapy in combinations. , 2014, Current opinion in immunology.

[31]  M. Hensel,et al.  Therapy of HIV-associated lymphoma—recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG) , 2014, Annals of Hematology.

[32]  L. Goldani,et al.  Consensus of the Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology on the management and treatment of Kaposi's sarcoma , 2014, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[33]  C. Leen,et al.  British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.) , 2014, HIV medicine.

[34]  C. Delaugerre,et al.  French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults , 2014, Journal of the International AIDS Society.

[35]  R. Davis,et al.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[36]  A. Petrich,et al.  Brentuximab vedotin in patients with relapsed HIV-related lymphoma. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[37]  T. Allen-Mersh,et al.  Salvage Surgery for Residual Primary and Locally Recurrent Anal Squamous Cell Carcinoma After Chemoradiotherapy in HIV-positive Individuals , 2014, Annals of Surgical Oncology.

[38]  E. Engels,et al.  Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[39]  C. Leen,et al.  British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013 , 2013, HIV medicine.

[40]  D. de Ruysscher,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  G. Guaraldi,et al.  Multicenter italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. , 2013, The oncologist.

[42]  B. Toll,et al.  Treatment of tobacco use in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[43]  L. Dal Maso,et al.  Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients , 2013, Anti-cancer drugs.

[44]  G. Nunnari,et al.  Hepatocellular carcinoma in HIV positive patients. , 2014, European review for medical and pharmacological sciences.

[45]  O. Farges,et al.  Standardized Care Management Ensures Similar Survival Rates in HIV-Positive and HIV-Negative Patients With Hepatocellular Carcinoma , 2012, Journal of acquired immune deficiency syndromes.

[46]  K. Armstrong,et al.  Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. , 2012, The Lancet. Oncology.

[47]  J. Rockstroh,et al.  Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Gribben,et al.  HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  D. Costagliola,et al.  Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  C. Verslype,et al.  Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  H. Zha,et al.  Epstein-Barr Virus Infection and Expression of B-cell Oncogenic Markers in HIV-Related Diffuse Large B-cell Lymphoma , 2012, Clinical Cancer Research.

[52]  S. Crystal,et al.  HIV as an independent risk factor for incident lung cancer , 2012, AIDS.

[53]  M. Haigentz,et al.  Lung cancer in HIV Infection. , 2012, Clinical lung cancer.

[54]  D. Klein,et al.  HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[55]  C. Flexner,et al.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS. , 2011, The Lancet. Oncology.

[56]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[57]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[58]  L. Siproudhis,et al.  Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study , 2011, International journal of cancer.

[59]  L. Quéro,et al.  Anal Carcinoma in HIV-Infected Patients in the Era of Antiretroviral Therapy: A Comparative Study , 2011, Diseases of the colon and rectum.

[60]  L. Cuzin,et al.  Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[62]  D. Samuel,et al.  Liver transplantation for hepatocellular carcinoma: The impact of human immunodeficiency virus infection , 2011, Hepatology.

[63]  G. Guaraldi,et al.  Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. , 2011, The oncologist.

[64]  D. Valla,et al.  Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report. , 2011, Hepato-gastroenterology.

[65]  J. Sparano,et al.  Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial , 2011, Cancer Chemotherapy and Pharmacology.

[66]  J. Margolick,et al.  Cancer incidence in the multicenter aids cohort study before and during the HAART era , 2010, Cancer.

[67]  L. Pantanowitz,et al.  Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. , 2010, Clinical lung cancer.

[68]  R. Pfeiffer,et al.  Age at Cancer Diagnosis Among Persons With AIDS in the United States , 2010, Annals of Internal Medicine.

[69]  S. Franceschi,et al.  Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study , 2010, British Journal of Cancer.

[70]  T. Gambichler,et al.  Anal carcinoma in human immunodeficiency virus‐positive men: results of a prospective study from Germany , 2010, The British journal of dermatology.

[71]  L. Abramowitz,et al.  Economic burden of anal cancer management in France. , 2010, Revue d'epidemiologie et de sante publique.

[72]  J. Northover,et al.  Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  C. Rödel,et al.  Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. , 2010, International journal of radiation oncology, biology, physics.

[74]  S. Khoo,et al.  Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. , 2010, Antiviral research.

[75]  M. Guiguet,et al.  Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.

[76]  S. Cole,et al.  A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.

[77]  E. Cesarman,et al.  Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  L. Pantanowitz,et al.  Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook , 2009, Current opinion in oncology.

[79]  T. Kinsella,et al.  Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. , 2009, International journal of radiation oncology, biology, physics.

[80]  I. Sobhani,et al.  Epidermoid anal cancer prognosis comparison among HIV+ and HIV− patients , 2009, Alimentary pharmacology & therapeutics.

[81]  S. Stryker,et al.  HIV and Anal Cancer Outcomes: A Single Institution's Experience , 2009, Diseases of the colon and rectum.

[82]  A. Kashuba,et al.  Drug Interactions with New and Investigational Antiretrovirals , 2009, Clinical pharmacokinetics.

[83]  E. Overton,et al.  The aging of the HIV epidemic , 2008, Current HIV/AIDS reports.

[84]  É. Oksenhendler,et al.  AIDS-related malignancies: state of the art and therapeutic challenges. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Halter,et al.  Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  G. Guaraldi,et al.  Human immunodeficiency virus and liver transplantation: our point of view. , 2008, Transplantation proceedings.

[87]  S. Montoto,et al.  British HIV Association guidelines for HIV‐associated malignancies 2008 , 2008, HIV medicine.

[88]  B. Seifert,et al.  HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  M. Masetti,et al.  Hepatocellular carcinoma in HIV patients treated by liver transplantation. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[90]  F. Innocenti,et al.  Lopinavir–Ritonavir Dramatically Affects the Pharmacokinetics of Irinotecan in HIV Patients With Kaposi's Sarcoma , 2008, Clinical pharmacology and therapeutics.

[91]  J. Rescigno,et al.  Invasive Anal Squamous-Cell Carcinoma in the HIV-Positive Patient: Outcome in the Era of Highly Active Antiretroviral Therapy , 2008, Diseases of the colon and rectum.

[92]  E. Bini,et al.  Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. , 2007, Journal of hepatology.

[93]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[94]  D. Vlahov,et al.  HIV infection is associated with an increased risk for lung cancer, independent of smoking. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  A. López-Guillermo,et al.  Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. , 2007, Haematologica.

[96]  J. Goedert,et al.  Elevated risk of lung cancer among people with AIDS , 2007, AIDS.

[97]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[98]  Richard D Moore,et al.  Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care , 2006, Journal of acquired immune deficiency syndromes.

[99]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[100]  F. Frizelle,et al.  MALIGNANT PROGRESSION OF ANAL INTRA‐EPITHELIAL NEOPLASIA , 2006, ANZ journal of surgery.

[101]  Richard D Moore,et al.  Elevated incidence of lung cancer among HIV-infected individuals. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  J. Palefsky,et al.  Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men , 2005, AIDS.

[103]  D. Euhus,et al.  Outcome of HIV-Infected Patients With Invasive Squamous-Cell Carcinoma of the Anal Canal in the Era of Highly Active Antiretroviral Therapy , 2004, Diseases of the colon and rectum.

[104]  V. Calvez,et al.  High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. , 2004, Haematologica.

[105]  J. Palefsky,et al.  Chapter 6: Immunosuppression and co-infection with HIV. , 2003, Journal of the National Cancer Institute. Monographs.

[106]  J. Goedert,et al.  Association of cancer with AIDS-related immunosuppression in adults. , 2001, JAMA.

[107]  K. Fife,et al.  Treatment of HIV-associated invasive anal cancer with combined chemoradiation. , 2000, European journal of cancer.

[108]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[109]  M. Ducreux,et al.  [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. , 1999, Bulletin du cancer.

[110]  J. Goedert,et al.  Spectrum of AIDS-associated malignant disorders , 1998, The Lancet.

[111]  R. Pazdur,et al.  Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. , 1993, American journal of clinical oncology.